<?xml version="1.0" encoding="UTF-8"?>
<p>Positive results regarding the effectiveness of RDV as a treatment for COVID-19 patients were also achieved in the Adaptive COVID-19 Treatment Trial (ACTT) financed by the National Institute of Allergy and Infectious Diseases (NIAID—part of the National Institutes of Health), a clinical trial that included 1063 patients: (i) patients treated with RDV (10 days—first day 200 mg/day intravenously, followed by 100 mg/day for 9 days) recovered faster (31%) as compared with patients that received placebo; in addition, the mortality rate was lower in the RDV-treated group compared with placebo (8% versus 11.6%, respectively) [
 <xref rid="B57-jcm-09-02084" ref-type="bibr">57</xref>]. The preliminary report results of the ACTT study were published by Beigel et al. in The New England Journal of Medicine on 22 May 2020 [
 <xref rid="B76-jcm-09-02084" ref-type="bibr">76</xref>]. On the basis of these preliminary promising data, European Medicine Agency (EMA) initiated the “rolling review” for RDV, resulting in the acceleration of the assessment process of RDV for marketing authorization [
 <xref rid="B77-jcm-09-02084" ref-type="bibr">77</xref>], while the FDA (Food and Drug Administration) authorized RDV for emergency use as a treatment for hospitalized COVID-19 patients [
 <xref rid="B78-jcm-09-02084" ref-type="bibr">78</xref>].
</p>
